Adalimumab improves HRQOL in AS
- PDF / 141,933 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 90 Downloads / 174 Views
Week 24
Adalimumab Placebo
Adalimumab Placebo
Change from baseline in QOL measure: SF-36 PCS +6.9** +1.6 SF-36 +2.7 +2.4 MCS* –3.2** –1.0 ASQoL
+7.4** +3.6
+1.9 +2.4
–3.6**
–1.1
* SF-36 Mental Component Summary ** p < 0.001 vs placebo
Compared with placebo, adalimumab was also associated with significant improvements from baseline in other SF-36 scores, including the physical function, bodily pain, role-physical, general health, vitality and role-emotional domains, at week 12. * This study was supported by Abbott Laboratories. Davis Jr JC, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis and Rheumatism 57: 1050-1057, No. 6, 15 Aug 801093497 2007
1173-5503/10/0538-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 6 Oct 2007 No. 538
1
Data Loading...
